Martin Brecher

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia
    Martin Brecher
    AstraZeneca Pharmaceuticals, Wilmington, DE, USA
    J Clin Psychiatry 68:597-603. 2007
  2. ncbi request reprint In response to Furst et al, "Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin"
    Wayne Geller
    Biol Psychiatry 52:914; author reply 914-5. 2002
  3. ncbi request reprint Rapid dose escalation with quetiapine: a pilot study
    Mark A Smith
    AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, PO Box 15437, Wilmington, DE 19850, USA
    J Clin Psychopharmacol 25:331-5. 2005
  4. doi request reprint Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia
    Hans Jurgen Moller
    Psychiatric Hospital of the University of Munich, Munich, Germany
    Int Clin Psychopharmacol 23:95-105. 2008
  5. ncbi request reprint The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy
    S Charles Schulz
    Department of Psychiatry, University of Minnesota Medical School, F282 2A West 2450 Riverside Avenue, Minneapolis, MN 55454, USA
    Schizophr Res 62:1-12. 2003
  6. ncbi request reprint Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia
    Siegfried Kasper
    Department of General Psychiatry, Medical University Vienna, Vienna, Austria
    Int Clin Psychopharmacol 19:281-9. 2004
  7. ncbi request reprint Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study
    Rene S Kahn
    Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands
    J Clin Psychiatry 68:832-42. 2007
  8. ncbi request reprint Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 163:1918-25. 2006
  9. ncbi request reprint Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder
    Caleb M Adler
    Center for Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Affect Disord 100:S15-22. 2007
  10. ncbi request reprint Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine
    Peter F Buckley
    Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Affect Disord 100:S33-43. 2007

Detail Information

Publications14

  1. ncbi request reprint Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia
    Martin Brecher
    AstraZeneca Pharmaceuticals, Wilmington, DE, USA
    J Clin Psychiatry 68:597-603. 2007
    ..To assess the magnitude and pattern of weight change during long-term treatment with the atypical antipsychotic quetiapine...
  2. ncbi request reprint In response to Furst et al, "Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin"
    Wayne Geller
    Biol Psychiatry 52:914; author reply 914-5. 2002
  3. ncbi request reprint Rapid dose escalation with quetiapine: a pilot study
    Mark A Smith
    AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, PO Box 15437, Wilmington, DE 19850, USA
    J Clin Psychopharmacol 25:331-5. 2005
    ....
  4. doi request reprint Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia
    Hans Jurgen Moller
    Psychiatric Hospital of the University of Munich, Munich, Germany
    Int Clin Psychopharmacol 23:95-105. 2008
    ..In conclusion, efficacy was maintained without compromising safety/tolerability when switching patients with stable schizophrenia from twice-daily quetiapine IR to once-daily quetiapine XR (400-800 mg/day)...
  5. ncbi request reprint The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy
    S Charles Schulz
    Department of Psychiatry, University of Minnesota Medical School, F282 2A West 2450 Riverside Avenue, Minneapolis, MN 55454, USA
    Schizophr Res 62:1-12. 2003
    ..The atypical antipsychotics that are currently commercially available are clozapine, risperidone, olanzapine, quetiapine, and ziprasidone. The focus of this report is on the efficacy of quetiapine...
  6. ncbi request reprint Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia
    Siegfried Kasper
    Department of General Psychiatry, Medical University Vienna, Vienna, Austria
    Int Clin Psychopharmacol 19:281-9. 2004
    ..In conclusion, quetiapine may be a suitable therapy in the long-term treatment of schizophrenia...
  7. ncbi request reprint Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study
    Rene S Kahn
    Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands
    J Clin Psychiatry 68:832-42. 2007
    ..To evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) in a 6-week, double-blind, randomized study...
  8. ncbi request reprint Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 163:1918-25. 2006
    ....
  9. ncbi request reprint Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder
    Caleb M Adler
    Center for Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
    J Affect Disord 100:S15-22. 2007
    ..To review the safety/tolerability of quetiapine in four placebo-controlled studies in patients with bipolar I disorder experiencing acute mania...
  10. ncbi request reprint Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine
    Peter F Buckley
    Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Affect Disord 100:S33-43. 2007
    ..Agitation and aggression are potentially disruptive and dangerous features of bipolar mania. This analysis evaluated the effects of quetiapine on agitation and aggression in patients with bipolar I mania...
  11. ncbi request reprint Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania
    Henry A Nasrallah
    University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Bipolar Disord 8:467-74. 2006
    ..To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania...
  12. ncbi request reprint Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
    Eur Neuropsychopharmacol 15:573-85. 2005
    ..The primary efficacy outcome variable was change from baseline to Day 21 in Young Mania Rating Scale (YMRS) score...
  13. ncbi request reprint Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies
    Eduard Vieta
    Hospital Clinic, August Pi i Sunyer Biomedical Research Institute IDIBAPS, University of Barcelona, Spain
    Curr Med Res Opin 21:923-34. 2005
    ..To evaluate the efficacy and safety of quetiapine monotherapy for mania in bipolar disorder by an a priori defined combined analysis of data from two placebo-controlled studies...
  14. ncbi request reprint A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder
    Charles L Bowden
    Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 66:111-21. 2005
    ..To evaluate the efficacy and tolerability of quetiapine monotherapy versus placebo for the treatment of mania associated with bipolar disorder...